STARTUP PROFILE

Blackrock Neurotech

COUNTRY
USA
FOUNDED
2008
CATEGORY
Brain-Computer Interface
Developer of the Utah Array, the first FDA-cleared BCI implant, enabling long-term neural recording and brain-controlled devices.
Visit website →
Market Notes · Biweekly

Track this company

Funding, launches and regulatory moves across the neurotech startup map.

Subscribed. Check your inbox to confirm.

Blackrock Neurotech

news and updates

  • 15 Jul 2026: A Science Translational Medicine study followed five people with spinal cord injury, each implanted with two Blackrock NeuroPort arrays in the somatosensory cortex. It reported no serious adverse events from intracortical microstimulation over 2 to 10 years of implantation. After more than 168 million pulses, 64% of electrodes still reliably evoked touch sensations.
  • 29 Apr 2024: Tether acquired a majority stake in Blackrock Neurotech for $200M. Read our analysis of BCI funding.
•
Neurofounders Insights
$   Funding   -
Series B
MODALITY
Intracortical
FORM FACTOR
Implant
INTERFACE DEPTH
Implantable
INDICATION
Paralysis/motor
TARGET USER
Mixed
REGULATORY STAGE
FDA cleared (510k)
Blackrock Neurotech is the longest-established intracortical BCI company, with the Utah Array having accumulated more documented long-term human implant data than any competing device in the field. Its Series B funding and FDA Breakthrough Designation position it as the reference platform against which newer implantable BCI entrants are benchmarked, though it faces increasing competitive pressure from companies pursuing less invasive approaches.
•
Mentioned in Market Notes
MOST RECENT COVERAGE
#
13
Neurotech wants to challenge GLP-1s
27 October – 10 November 2026

Blackrock Neurotech’s Utah Array was used in an auditory nerve implant that passed bench testing, with nearly all electrodes surviving 1.5 years of simulated aging and 6.3 billion stimulation pulses. The team calls it a step toward first-in-human trials.

Articles featuring
Blackrock Neurotech